Mount Sinai receives NIH grant to study use of inhaled corticosteroids for sickle cell treatment | oneSCDvoice
  • Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Mount Sinai receives NIH grant to study use of inhaled corticosteroids for sickle cell treatment


The Departments of Emergency Medicine and Hematology at the Icahn School of Medicine at Mount Sinai have been awarded a $4 million grant from the National Institutes of Health toward further study of inhaled corticosteroids to treat sickle cell disease (SCD) in individuals who do not have asthma. The IMPROVE 2 study is a one-year randomized, placebo-controlled trial involving 80 SCD patients.

According to the U.S. Centers for Disease Control and Prevention, SCD affects 100,000 Americans and is more prevalent in certain ethnic groups, such as African Americans and Hispanic Americans. The Healthcare Cost and Utilization Project, a database consortium sponsored by the federal government, reports that per-patient health care costs in the U.S. are higher for SCD than any other disease, with total expenditures exceeding $2.4 billion.

https://www.onescdvoice.com/wp-content/uploads/2018/08/Mount_Sinai_hospital.png